Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer
Molecules · 2024
DOI: 10.3390/molecules29246062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Ratu Ralna Ismuha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia. Hauptthemen laut MEDLINE: Radioisotopes, Prostatic Neoplasms, Castration-Resistant, Radiopharmaceuticals, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dharmais Cancer Hospital, Coordinated Research Project (CRP) International Atomic Energy Agency, Universitas Padjadjaran.
Abstract (Originalsprache)
Prostate cancer ranks as the fourth most common cancer among men, with approximately 1.47 million new cases reported annually. The emergence of prostate-specific membrane antigen (PSMA) as a critical biomarker has revolutionized the diagnosis and treatment of prostate cancer. Recent advancements in low-molecular-weight PSMA inhibitors, with their diverse chemical structures and binding properties, have opened new avenues for research and therapeutic applications in prostate cancer management. These novel agents exhibit enhanced tumor targeting and specificity due to their small size, facilitating rapid uptake and localization at the target site while minimizing the retention in non-target tissues. The primary aim of this study is to evaluate the potential of low-molecular-weight PSMA inhibitors labeled with radioisotopes as theranostic agents for prostate cancer. This includes assessing their efficacy in targeted imaging and therapy and understanding their pharmacokinetic properties and mechanisms of action. This study is a literature review focusing on in vitro and clinical research data. The in vitro studies utilize PSMA-targeted radioligands labeled with radioisotopes to assess their binding affinity, specificity, and internalization in prostate cancer cell lines. Additionally, the clinical studies evaluate the safety, effectiveness, and biodistribution of radiolabeled PSMA ligands in patients with advanced prostate cancer. The findings indicate promising outcomes regarding the safety and efficacy of PSMA-targeted radiopharmaceuticals in clinical settings. The specific accumulation of these agents in prostate tumor lesions suggests their potential for various applications, including imaging and therapy. This research underscores the promise of radiopharmaceuticals targeting PSMA in advancing the diagnosis and treatment of prostate cancer. These agents improve diagnostic accuracy and patients’ outcomes by enhancing imaging capabilities and enabling personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.
- Department of Pharmacy, Dharmais Cancer Hospital-National Cancer Center, Jakarta 11420, Indonesia.
- Center for Research on Radioisotope Technology, Radiopharmaceuticals, and Biodosimetry, National Research and Innovation Agency (BRIN), South Tangerang 15314, Indonesia.
- Research Collaboration Centre for Radiopharmaceuticals Theranostic, National Research and Innovation Agency (BRIN), Sumedang 45363, Indonesia.
ORCID-Profile: Ratu Ralna Ismuha, Rien Ritawidya, Isti Daruwati, Muchtaridi Muchtaridi
Förderung
- Dharmais Cancer Hospital
- Coordinated Research Project (CRP) International Atomic Energy Agency
- Universitas Padjadjaran
Zitieren
APA
Ismuha, R. R., Ritawidya, R., Daruwati, I., & Muchtaridi, M. (2024). Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer. Molecules. https://doi.org/10.3390/molecules29246062
Vancouver
Ismuha RR, Ritawidya R, Daruwati I, Muchtaridi M. Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer. Molecules. 2024. doi:10.3390/molecules29246062
BibTeX
@article{Ismuha2024,
author = {Ismuha, Ratu Ralna and Ritawidya, Rien and Daruwati, Isti and Muchtaridi, Muchtaridi},
title = {Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29246062}
}
EUVIMED